Morphic Medical’s non-invasive weight loss device RESET is expected to secure Medicines and Healthcare products Regulatory Agency (MHRA) registration in the coming weeks, paving the way for a UK launch, according to majority shareholder Crystal Amber Fund.

The UK activist investment fund, which owns 98% of Morphic Medical, issued an update today stating that MHRA registration would confirm that RESET meets UK safety and performance requirements. The device is already CE marked and has launched in Germany, with other EU rollouts planned.

RESET is a removable intestinal sleeve designed to delay food contact with the gut lining. Clinical studies suggest the device helps reduce weight by an average of 19%, with 77% of patients maintaining the benefits three years after removal. The 20-minute outpatient procedure is positioned as a less invasive alternative to gastric surgery and potentially more sustainable than GLP-1 drugs.

The UK’s estimated £126 billion annual obesity burden presents a substantial potential market for RESET. According to Crystal Amber, approximately 1.6 million patients in the UK could benefit.

RESET is also undergoing a pivotal study under the US FDA fast-track pathway. FDA approval is targeted for the second half of 2027. The company is reportedly in talks with multinational device manufacturers, with one S&P 500 firm said to be considering a US$5–10 million investment.

Crystal Amber has invested $5.15 million into Morphic Medical since January and expects to provide further capital in the coming weeks. It confirmed today that it would retain its stake in the company, citing growing investor interest and ongoing regulatory progress.